治疗药物监测指导阿尔茨海默病中利培酮的安全处方
本研究基于痴呆患者利培酮随机对照试验数据,采用非线性混合效应模型贝叶斯方法分析药代动力学。年龄显著影响利培酮清除率(β=-1.5),肾小球滤过率影响9-羟基利培酮清除率(β=0.2)。模型预测26.2%(95%CI 18.6-32.6%)的患者活性部分浓度-剂量比超过14 ng/mL per mg/day,支持治疗药物监测必要性。
要点
- 年龄显著影响利培酮清除率,需根据年龄调整剂量。
- 26.2%患者活性部分C/D比超过14 ng/mL per mg/day毒性阈值。
- 治疗初期应进行治疗药物监测以识别毒性高风险患者。
核心结论
- 年龄相关利培酮剂量调整很重要,治疗初期应进行治疗药物监测以识别毒性高风险患者。
研究设计与样本
- 基于痴呆患者利培酮随机对照试验数据的非线性混合效应模型分析,采用贝叶斯方法,协变量包括年龄和肾小球滤过率。
主要发现
- 年龄对利培酮清除率有显著影响(β=-1.5),肾小球滤过率对9-羟基利培酮清除率有显著影响(β=0.2)。
- 模型预测26.2%(95%CI 18.6-32.6%)的患者活性部分C/D比超过14 ng/mL per mg/day。
关键数值与推荐
- 活性部分(利培酮和9-羟基利培酮)C/D比高于14 ng/mL per mg/day与锥体外系副作用风险增加相关。
临床怎么用
- 在痴呆患者初始治疗阶段进行治疗药物监测,识别C/D比超过14 ng/mL per mg/day的高风险患者。
- 根据年龄调整利培酮剂量以降低毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous analysis of pharmacokinetic data on risperidone-treated patients with dementia predicted that 20% had concentration-to-dose (C/D) ratios of the active moiety (risperidone and 9-hydroxy(OH)-risperidone) above 14 ng/mL per mg/day, which were in turn associated with a greater risk of extrapyramidal side effects. This study aimed to further explore risperidone pharmacokinetics in a second dataset. Nonlinear mixed effects modelling, using a Bayesian approach, was applied to data from a randomized controlled trial of risperidone in people with dementia. Covariates included age and glomerular filtration rate (GFR). Age had a significant effect on risperidone clearance (β = -1.5) and GFR on 9-OH-risperidone clearance (β = 0.2). The model predicted that 26.2% (95% confidence interval 18.6-32.6%) had C/D ratios above 14 ng/mL per mg/day. These findings confirm the importance of age-related risperidone dose adjustments and argue strongly for therapeutic drug monitoring in the initial stages of treatment to identify those at greatest risk of toxicity.
引用
- Roughley M, Mena C, Howard R, et al. Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring. Br J Clin Pharmacol. 2023. PMID: 36791792. doi:10.1111/bcp.15692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。